Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

ViaCyte

Biotech & Life Sciences · San Diego, United States · Founded 1999

ViaCyte is a pioneering company in the field of regenerative medicine, dedicated to developing innovative stem cell-derived therapies aimed at treating diabetes. The company focuses on creating cell replacement therapies that could potentially serve as a functional cure for type 1 diabetes and provide advanced treatment options for insulin-requiring type 2 diabetes. ViaCyte operates primarily in the healthcare and biotechnology market, targeting patients with insulin-dependent diabetes. Their primary clients include individuals suffering from type 1 diabetes, especially those at high risk of severe complications, and patients with type 2 diabetes who require insulin. The company's business model revolves around the research, development, and commercialization of its proprietary cell replacement therapies. ViaCyte's key products include PEC Direct and PEC Encap, both of which are currently in clinical trials. PEC Direct is designed for high-risk type 1 diabetes patients, while PEC Encap aims to offer a functional cure for type 1 diabetes. Additionally, ViaCyte has partnered with CRISPR Therapeutics on the PEC QT program to develop next-generation therapies for all insulin-requiring diabetes. ViaCyte generates revenue through the development and eventual commercialization of its therapies. This includes potential income from licensing agreements, partnerships, and future sales of their therapeutic products once they receive regulatory approval. In summary, ViaCyte is at the forefront of regenerative medicine, striving to transform the treatment landscape for diabetes through innovative stem cell-derived therapies. Their commitment to developing functional cures and advanced treatments positions them as a key player in the biotechnology and healthcare sectors. Keywords: regenerative medicine, stem cell therapy, diabetes treatment, type 1 diabetes, type 2 diabetes, PEC Direct, PEC Encap, clinical trials, biotechnology, healthcare.

Valuation
$100–500M
Latest valuation · 2022
Unlock exact value
Headcount
<100
Current team size
Unlock exact value
Total funding Pre-IPO
$100–500M
Unlock exact value

Investors

19 investors on ViaCyte's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
California Institute for Regenerative Medicine
National Institute of Diabetes and Digestive and Kidney Diseases
Series B+ 17 investors entered at this stage
BD Ventures
The Vertical Group
Johnson & Johnson Development Corporation
DFJ Portage Ventures
Headland Ventures
Asset Management Ventures
Sanderling Ventures
Pacific Horizon Ventures
Valterna
Bain Capital Life Sciences
RA Capital Management
TPG
Invus
Adage Capital
Artis Ventures
Asymmetry Ventures
Bain Capital

Global footprint

Where ViaCyte has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Talent graph

The shape of ViaCyte's talent

Dealroom maps ViaCyte's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

14 team members profilednamed & role-tagged by Dealroom
14 employeestotal headcount
2 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock ViaCyte's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about ViaCyte

An AI-synthesized read of the highest-engagement posts about ViaCyte on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ViaCyte on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.